Tempus AI announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. The company expects genomics revenue to grow approximately 30% in Q4 and data and services revenue to grow approximately 45% in Q4.
For the full year 2024, Tempus expects to deliver approximately 99% of its revenue guidance and approximately 100% of its adjusted EBITDA guidance. This indicates continued strength in its core businesses despite some softness in CRO revenues.
The announcement comes ahead of the company’s presentation at the 43rd Annual J.P. Morgan Healthcare Conference. An updated investor deck, including an update on the expected closing of the Ambry acquisition, is available on the company's investor relations website.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.